These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 482136)
1. [Dipyridamole pharmacokinetics in liver diseases]. Markiewicz A; Semenowicz K; Korczyńska J Pol Arch Med Wewn; 1979 Jun; 61(6):463-70. PubMed ID: 482136 [No Abstract] [Full Text] [Related]
2. Chronopharmacokinetics of dipyridamole. Markiewicz A; Semenowicz K; Korczynska J; Czachowska A Int J Clin Pharmacol Biopharm; 1979 May; 17(5):222-4. PubMed ID: 468446 [TBL] [Abstract][Full Text] [Related]
3. Pathways and tissue distribution of dipyridamole (Persantin). Mellinger TJ; Bohorfoush JG Arch Int Pharmacodyn Ther; 1965 Aug; 156(2):380-8. PubMed ID: 5895707 [No Abstract] [Full Text] [Related]
4. Does a rhythmicity of serum concentrations and urinary excretion of dipyridamole exist during long-term treatment? Markiewicz A; Semenowicz K Pol J Pharmacol Pharm; 1980; 32(3):289-95. PubMed ID: 7197020 [TBL] [Abstract][Full Text] [Related]
5. Dipyridamole disposition after chronic administration: effect of aspirin. Rosenfeld J; Buchanan MR; Reilly PA; Turpie AG Thromb Res Suppl; 1983; 4():137-43. PubMed ID: 6579707 [No Abstract] [Full Text] [Related]
6. The bioavailability of three dipyridamole products. Markiewicz A; Hartleb M; Boldys H Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):499-501. PubMed ID: 6642785 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in dogs. Stracciari GL; Malvisi J; Anfossi P; Fregnan GB Arch Int Pharmacodyn Ther; 1989; 300():7-13. PubMed ID: 2619427 [TBL] [Abstract][Full Text] [Related]
8. Comparison of bioavailability of two dipyridamole formulations. Markiewicz A; Semenowicz K; Szczyrba E; Kocek B Pol J Pharmacol Pharm; 1978; 30(5):605-9. PubMed ID: 582068 [TBL] [Abstract][Full Text] [Related]
9. The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison. Terhaag B; Donath F; Le Petit G; Feller K Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):298-302. PubMed ID: 3733279 [TBL] [Abstract][Full Text] [Related]
10. [Influence of the aspirin-dipyridamole combination in man and animal on their respective blood kinetics]. Decourt S; Hazard MC; Beyne P; Paris J; Fayard JM; Flouvat B Therapie; 1983; 38(3):255-63. PubMed ID: 6612662 [No Abstract] [Full Text] [Related]
12. [The bioavailability of dipyridamole in the form of liposomes]. Stozek T; Krówczyński L Pharmazie; 1986 Sep; 41(9):645-7. PubMed ID: 3797455 [TBL] [Abstract][Full Text] [Related]
13. [Study of the individual factor and the plasma-organ concentration relationship in rats treated with dipyridamol. I. The heart]. Jiménez-Castellanos R; Fernández R; Faulí C Boll Chim Farm; 1984 Jul; 123(7):322-9. PubMed ID: 6518090 [No Abstract] [Full Text] [Related]
14. Thermodynamic differences between the binding interaction of nitrobenzylthioinosine and dipyridamole with the nucleoside transport system of human erythrocytes. Clanachan AS; Hammond JR Proc West Pharmacol Soc; 1983; 26():251-3. PubMed ID: 6889349 [No Abstract] [Full Text] [Related]
16. [Effect of liver diseases on pharmacokinetics of drugs]. Lazowski J; Rewerski W Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):95-9. PubMed ID: 2216955 [No Abstract] [Full Text] [Related]
17. Absorption and activity of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d) pyrimidine (RA8) following enteric administration. Kadatz R; Beisenherz G Arch Int Pharmacodyn Ther; 1965 Dec; 158(2):389-402. PubMed ID: 5868589 [No Abstract] [Full Text] [Related]